Research Papers:

Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export

Jasper Edgar Neggers, Els Vanstreels, Erkan Baloglu, Sharon Shacham, Yosef Landesman and Dirk Daelemans _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:68842-68850. https://doi.org/10.18632/oncotarget.11995

Metrics: PDF 1585 views  |   HTML 3469 views  |   ?  


Jasper Edgar Neggers1, Els Vanstreels1, Erkan Baloglu2, Sharon Shacham2, Yosef Landesman2, Dirk Daelemans1

1Katholieke Universiteit Leuven, Department of Immunology and Microbiology, Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, Leuven, Belgium

2Karyopharm Therapeutics, Newton, MA, USA

Correspondence to:

Dirk Daelemans, email: [email protected]

Keywords: XPO1, CRM1, SINE, CRISPR/Cas9, nuclear export

Received: April 22, 2016    Accepted: August 24, 2016    Published: September 13, 2016


Exportin-1 (CRM1/XPO1) is a crucial nuclear export protein that transports a wide variety of proteins from the nucleus to the cytoplasm. These cargo proteins include tumor suppressors and growth-regulatory factors and as such XPO1 is considered a potential anti-cancer target. From this perspective, inhibition of the XPO1-mediated nuclear export by selective inhibitor of nuclear export (SINE) compounds has shown broad-spectrum anti-cancer activity. Furthermore, the clinical candidate SINE, selinexor, is currently in multiple phase I/II/IIb trials for treatment of cancer. Resistance against selinexor has not yet been observed in the clinic, but in vitro selection of resistance did not reveal any mutations in the target protein, XPO1. However, introduction of a homozygous mutation at the drug’s target site, the cysteine 528 residue inside the XPO1 cargo-binding pocket, by genetic engineering, confers resistance to selinexor. Here we investigated whether this resistance to selinexor is recessive or dominant. For this purpose we have engineered multiple leukemia cell lines containing heterozygous or homozygous C528S substitutions using CRISPR/Cas9-mediated genome editing. Our findings show that heterozygous mutation confers similar resistance against selinexor as homozygous substitution, demonstrating that SINE resistance can be obtained by a single and dominant mutation of the cysteine528 residue in XPO1.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11995